Longevity Based Releases New Report on Biohacking Recovery Technologies Used in CEO Jacob Gendron’s Longevity Routine




Longevity Based Releases New Report on Biohacking Recovery Technologies Used in CEO Jacob Gendron’s Longevity Routine

Plant-based nutrition, strength training, and biohacking technology support his measured heart health.

Los Angeles, CA, March 10, 2026 (GLOBE NEWSWIRE) — Longevity Based, a Los Angeles-based wellness brand focused on biohacking devices and longevity technology, announced today the release of a new report examining recovery technologies used in the structured wellness routine followed by CEO Jacob Gendron. The report outlines how nutrition, strength training, daily movement, and recovery tools are incorporated into long-term health tracking. Data referenced in the report includes wearable tracking metrics, which showed Gendron’s heart age measured at 22, approximately 25 percent younger than his biological age of 30.

Longevity Based CEO Jacob Gendron on Mt. Whitney peak

His routine combines a plant-based diet, three weekly strength workouts, daily movement, targeted nutrition, and recovery tools including red light therapy panels, cold plunge tubs, and other longevity devices.

At the center of Gendron’s routine is a plant-based diet and a consistent training schedule built around three workouts per week. His workouts include compound lifts such as deadlifts, squats, and cleans, helping support strength, conditioning, and long-term cardiovascular performance.

Outside the gym, Gendron stays active throughout the workday by using a standing desk to reduce sedentary time. His broader nutrition routine includes estrogen reducing plant foods frequently discussed in recent medical literature, including black cumin, turmeric, ginger, green tea, and decaf coffee.

Recovery and performance tools are also part of the routine. Gendron regularly uses red light therapy panels, along with other wellness technologies commonly used in modern recovery environments. These include red light therapy pads, handheld red light therapy devices, and infrared wellness tools designed to support recovery and performance.

Beyond recovery tools, Longevity Based offers a wide range of the best biohacking devices used across health, fitness, and aesthetic wellness. These include cold plunge systems, saunas, PEMF mats, infrared mats, and measurement devices used to track health metrics.

The company’s catalog also includes aesthetic and wellness technologies such as facial treatment machines, RF devices, laser systems, microneedling devices, ultrasound machines, and body contouring devices. Additional biohacking products and recovery technologies include EMS devices, exercise bikes, and advanced recovery equipment designed for both home and professional use.

The company notes that these habits are reflected not only in daily tracking but also in real-world performance. In August 2025, Gendron completed a one-day hike of Mt. Whitney, a demanding endurance challenge that reflects the physical conditioning and consistency behind his long-term approach to health.

“The best biohacking devices are most effective when they support a strong foundation of daily habits,” said Jacob Gendron, CEO of Longevity Based. “For me, that means a plant-based diet, strength training three times per week, staying active throughout the day, and using recovery tools like red light therapy panels as part of a sustainable long-term routine.”

By sharing Gendron’s routine, Longevity Based aims to show how modern biohacking gadgets can fit into a broader lifestyle centered on consistency, recovery, and performance rather than quick fixes. Readers can learn more about the company’s longevity products and visit the longevity blog for additional insights on health technology and recovery tools.

About Longevity Based

Longevity Based is a wellness brand focused on biohacking products, including red light therapy panels and anti-aging equipment, along with educational content designed to support long-term health, recovery, and performance.

Press Inquiries

Jacob Gendron
partner@longevitybased.com
https://longevitybased.com

Medicare Advantage Mental Health Coverage in New York: $0–$30 Online Therapy Sessions




Medicare Advantage Mental Health Coverage in New York: $0–$30 Online Therapy Sessions

Manhattan Mental Health Counseling, the highest-rated affordable online therapy practice is now in-network with five major Medicare Advantage carriers. They now cover 78% of the state’s 1.8 million beneficiaries.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) — Manhattan Mental Health Counseling (MMHC), A rapidly growing, New York-based outpatient telehealth psychotherapy practice today announced expanded Medicare Advantage mental health coverage. Now in-network with five major carriers, the practice offers licensed mental health therapy to New York seniors at copays as low as $0 per session, with no referral needed on most plans.

MMHC accepts Healthfirst, Molina Healthcare, United Healthcare, EmblemHealth (VIP Medicare), and Fidelis Care, carriers that together serve 78% of New York’s 1.8 million Medicare Advantage beneficiaries. The practice has assembled a dedicated Medicare billing team and a roster of geriatric-trained therapists to support the program, with first sessions available the same week a patient reaches out.

MMHC provides online therapy to Medicare Advantage members throughout New York State, including New York City, Brooklyn, Queens, Manhattan, the Bronx, Long Island, Westchester County, and upstate regions.

The expansion reflects growing demand for Medicare Advantage mental health coverage in New York, particularly among older adults seeking convenient telehealth options that remove transportation and access barriers.

“Later life brings major transitions: retirement, health changes, grief, and caregiving responsibilities. Therapy can be incredibly valuable during those periods, and many Medicare Advantage plans already cover it. We focus on helping seniors understand their benefits and start care quickly.”
— Steven Buchwald, Managing Director, Manhattan Mental Health Counseling

Medicare Advantage members can verify benefits and schedule a first appointment at:

https://manhattanmentalhealthcounseling.com/medicare-advantage-online-therapy-in-new-york/

Understanding Medicare Advantage Mental Health Coverage in New York

Medicare Advantage Mental Health coverage is often more generous than beneficiaries realize. Under federal law, Medicare Advantage mental health coverage must provide at least the same mental health benefits as Original Medicare. In practice, many Medicare Advantage plans in New York go further: replacing the standard 20% coinsurance after a deductible with a fixed $0–$30 copay per session, and many plans offer online therapy covered by Medicare Advantage at the same rate as in-person care.

MMHC accepts Medicare Advantage plans from major carriers across New York State.

“Medicare Advantage billing requires careful credentialing and claims management. We’ve built a dedicated intake and billing workflow so patients can access therapy without dealing with the complexity behind the scenes.”
— Holly Jones, Credentialing & Workflow Lead, Manhattan Mental Health Counseling

Which Medicare Advantage Plans Does MMHC Accept?

MMHC is in-network with the following Medicare Advantage carriers across New York State:

1. Healthfirst (HMO, PPO & Dual Advantage)
2. Molina Healthcare (HMO)
3. United Healthcare Medicare Advantage (HMO, PPO)
4. EmblemHealth VIP Medicare
5. Fidelis Care (HMO, PPO)

All five carriers cover telehealth mental health services, and many plans apply the same copay for telehealth as for in-person care. MMHC’s billing team manages all claims submissions directly, patients do not need to file paperwork themselves.

What Conditions Do MMHC’s Senior Therapists Treat?

MMHC’s geriatric-trained therapists specialize in the mental health challenges most prevalent among adults 65 and older, including:

1. Depression, anxiety, and adjustment disorders related to retirement, health changes, and life transitions
2. Grief and bereavement after loss of a spouse, partner, or lifelong friends
3. Caregiver stress for those managing a loved one’s care
4. Social isolation, loneliness, and chronic illness adjustment
5. End-of-life existential concerns and advance care planning discussions

Evidence-based modalities used include Cognitive Behavioral Therapy (CBT) adapted for older adults, Interpersonal Therapy (IPT), Problem-Solving Therapy (PST), Acceptance and Commitment Therapy (ACT), and mindfulness-based interventions.

About Manhattan Mental Health Counseling

Manhattan Mental Health Counseling (MMHC) is a New York-based telehealth practice with 80+ clinicians specializing in anxiety, trauma, life transitions, and geriatric mental health. The practice is in-network with major commercial and government-sponsored insurance plans throughout New York State.

For more information, visit manhattanmentalhealthcounseling.com or call 212-960-8626.

Frequently Asked Questions

Do I need a referral from my doctor to start therapy under Medicare Advantage?

Most Medicare Advantage plans accepted by MMHC allow self-referral for mental health services. MMHC’s intake team confirms referral requirements for your specific plan during benefits verification.

How many therapy sessions will Medicare pay for each year?

Medicare Advantage plans generally do not impose a fixed annual session limit for outpatient mental health therapy. Coverage is based on medical necessity as documented by your therapist. Many MMHC patients continue therapy on an ongoing basis as a proactive investment in long-term wellbeing.

R1 and Heidi Announce Strategic Partnership to Improve Revenue Capture for Physician Groups and Healthcare Organizations




R1 and Heidi Announce Strategic Partnership to Improve Revenue Capture for Physician Groups and Healthcare Organizations

Partnership Integrates Heidi’s AI scribe technology into R1’s Phare Revenue Operating System, Bringing Reimbursement Accuracy into the Clinical Workflow

CHICAGO and NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) — R1, the leader in healthcare revenue management, and Heidi, the leading AI-powered care partner, today announced a strategic partnership. Together, R1 and Heidi will combine clinician focused documentation workflow with revenue management technology to link care delivery and reimbursement processes for providers across the healthcare ecosystem.

Today, physicians are confronted by administrative complexity and busy work, while inefficiency in the translation between clinical documentation and the revenue cycle leads to revenue loss for healthcare providers. This partnership addresses both sides of the problem by connecting clinical and financial intelligence, creating an integrated operating layer that orchestrates the care-to-cash continuum.

Heidi, the most adopted ambient AI scribe globally, supports more than 2.7 million visits a week by capturing comprehensive clinical details directly within the physician workflow. R1, through its Phare Revenue Operating System, translates this clinical intelligence into accurate and compliant claims. The result is a system that allows physicians to focus on practicing medicine and healthcare organizations to avoid denials, prevent defects, and improve revenue recovery.

Together, R1 and Heidi are focused on accurately capturing the scope and complexity of the work physicians perform and ensuring providers capture the full value of the care they provide. Heidi users will see greater visibility into payer policy information, prior authorization rules and insurance eligibility information at the point of care. Notes written in Heidi will be optimized to ensure accurate coding and billing, reducing the risk of down-coding, missed billable procedures and medical necessity denials. Revenue cycle practitioners will see higher-quality documentation entering billing workflows, with faster claim processing and improved reimbursement predictability.

Historically, healthcare providers have relied on fragmented solutions to address individual steps in these workflows. R1 and Heidi are closing the gap between documentation and revenue, moving the industry towards a fully integrated Revenue Operating System.

“By integrating Heidi Health’s technology into R1’s Phare Revenue Operating System, we’re bringing revenue intelligence directly into the physician workflow,” said Joe Flanagan, Chief Executive Officer of R1. “Healthcare organizations can reduce clinical burden and improve financial performance, capturing the full value of care with a reimbursement operating system that is precise, compliant and efficient.”

“Clinicians should be able to focus fully on their patients and have confidence that the system around them will handle the rest,” said Dr. Thomas Kelly, Co-Founder and Chief Executive Officer of Heidi. “Revenue management companies have historically had limited integration with clinicians, while scribe companies have lacked system-level payer data. This important partnership changes that. By connecting R1’s payer intelligence directly with Heidi’s platform at the point of care, we can deliver real-time billing and authorization guidance the moment it matters. Together we can close a gap that costs the whole system billions.”

About R1
R1 is the leader in healthcare revenue management, helping providers achieve new levels of performance through smart orchestration. A pioneer in the industry, R1 created the first Healthcare Revenue Operating System: a modular, intelligent platform that integrates automation, AI, and human expertise to strengthen the entire revenue cycle. With more than 20 years of experience, R1 partners with 1,000 providers, including 95 of the top 100 U.S. health systems, and handles over 270 million payer transactions annually. This scale provides unmatched operational insight to help healthcare organizations unlock greater long-term value. To learn more, visit: r1rcm.com.

About Heidi
Heidi is building an AI Care Partner, with a mission to double the world’s healthcare capacity by supporting every stage of care delivery. In addition to its popular AI scribe, Heidi has introduced Evidence – giving clinicians access to trusted medical research to support clinical decision at the point of care – and Comms, a calls function that enables healthcare teams to coordinate patient communications. Together, these capabilities support various aspects of the clinical workflow, enabling clinicians to focus on providing quality patient care. Heidi supports more than 2.5 million consults each week in 110 languages from 190 countries. Founded in Melbourne, Australia, Heidi has raised $96.6M USD from global investors including Point72 Private Investments, Blackbird, Headline, Phoenix Court’s growth fund – Latitude, Possible Ventures, and Archangel. Heidi adheres to international standards including the NHS, HIPAA, GDPR, and Australian Privacy Principles, and has obtained enterprise-grade security certifications such as SOC2 and ISO27001.

Contacts
R1
Will Reilly
VP, Marketing
media@r1rcm.com

Eliza Rothstein / Madeline Jones
Joele Frank, Wilkinson Brimmer Katcher
R1RCM-JF@joelefrank.com

Contacts
Heidi
Mackenzie Kreitler
mkreitler@heycommand.com

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2026




EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2026

Disclosure of Share Capital and Voting Rights Outstanding
as of February 28, 2026

(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Paris, France (March 10, 2026 – 6:00 pm) – As of February 28, 2026, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated below.

It is to be noted that voting rights are capped at 31%, applicable to any shareholder, in accordance with a formula contained in article 23 of EssilorLuxottica’s by-laws¹.

¹EssilorLuxottica’s by-laws are available on the Company’s website under the section Governance / Publications.

Attachment

• DOWNLOAD THE PRESS RELEASE

Orion Corporation: Managers’ transactions – Liisa Hurme




Orion Corporation: Managers’ transactions – Liisa Hurme

ORION CORPORATION
MANAGERS’ TRANSACTIONS
10 MARCH 2026 at 17.00 EET
        

Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Liisa Hurme
Position: Chief Executive Officer
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 146377/6/6

____________________________________________
Transaction date: 2026-03-10
Outside a trading venue
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details
(1): Volume: 14700 Unit price: 0 EUR

Aggregated transactions (1):
Volume: 14700 Volume weighted average price: 0 EUR

Orion Corporation

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.

Nominations Now Open for PerfectServe’s Sixth Annual Nurses of Note Awards Program




Nominations Now Open for PerfectServe’s Sixth Annual Nurses of Note Awards Program

2026 program to highlight nurse leadership and excellence in clinical innovation, patient-centered care, culture & retention, and care team communication

MIAMI, March 10, 2026 (GLOBE NEWSWIRE) — PerfectServe^®, a leading healthcare technology company specializing in unified clinical communication and provider scheduling solutions, today announced that nominations are now open for the sixth annual Nurses of Note awards program. Submissions will be accepted through April 10, and winners will be announced on May 12 to coincide with National Nurses Week.

The program has recognized over 500 nurses since its inception in 2021, representing a multitude of care settings and nursing roles.

“There’s nothing nearer and dearer to my heart than celebrating nurses,” said PerfectServe Chief Customer Officer & Chief Clinical Officer Kelly Conklin. “Far too often, their work is either unseen or undervalued, and as someone who spent 20 years at the bedside, I know what a tremendous impact a good nurse can have on a patient who might be going through one of the most challenging periods in their life. Nurses of Note gives us a chance to bring these stories to the forefront in a joyful way.”

The theme for the 2026 program is nurse leadership, with awards being broken into four specific categories to capture some of the unique ways nurses can impact patient care, clinical workflows, and team culture:

• The Clinical Innovation & Impact Award will recognize a nurse who drives meaningful improvements in clinical practice, technology, or care delivery, turning innovative ideas into tangible impact for patients, teams, or their organization.
• The Care Team Communication Award will honor a nurse who strengthens care team communication and workflows across their team or department(s), helping colleagues work together more efficiently and collaboratively
• The Excellence in Patient-Centered Care Award will acknowledge a nurse who leads by example in providing exceptional, patient-centered care while inspiring colleagues and influencing practices or standards within their organization.
• The Culture & Retention Award will celebrate a nurse who fosters a positive team culture through mentorship, support, and advocacy, helping colleagues thrive and contributing to engagement and long-term retention.

A grand prize winner will be selected for each of the four categories. Winners will receive prizes including a gift card, additional cash to invest in their team, and they’ll also be featured in detailed profiles on the PerfectServe blog, which will be highlighted across the company’s social media channels.

Kyle Pingleton, the recipient of the 2025 Excellence in Nursing Leadership Award who serves as Director of Quality Management at Cornerstone Specialty Hospitals Broken Arrow in Broken Arrow, OK, said the Nurses of Note recognition was a career highlight: “Receiving this award from PerfectServe, including an on-site visit from one of their leaders that allowed me to celebrate with my whole team, was a reminder that the world is a better place when you bring a little positive energy. Nurses move mountains every day, and I wish we could do so much more to recognize their contributions. I appreciate PerfectServe’s consistent efforts to bring their work to light, and I look forward to reading about this year’s winners!”

To learn more about the program or submit a nomination, visit PerfectServe.com.

About PerfectServe
PerfectServe accelerates speed to care by optimizing provider schedules, streamlining clinical communication, and engaging patients and their families in the care experience. Our cloud-based software simplifies complex clinical workflows and schedules with secure and timely communication by dynamically routing messages to the right person at the right time. We drive more efficient care collaboration in all settings to improve patient outcomes and bring joy back to caregivers. PerfectServe has over 25 years of experience and is a trusted partner to more than 500 hospitals and 30,000 medical practices.

PerfectServe Contact:
Matt Kothe | Director, Corporate Marketing
865.776.9824
mkothe@perfectserve.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/92f6999a-174c-4f40-b79c-5eef0f84d2c4

Imprivata Introduces Agentic Identity Management to Secure and Govern AI Agents in Healthcare




Imprivata Introduces Agentic Identity Management to Secure and Govern AI Agents in Healthcare

New capabilities enable healthcare organizations to deploy AI agents that improve clinician productivity while maintaining secure, compliant access across modern and legacy systems

WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) — HIMSS 2026, Las Vegas (booth #2453) — Imprivata, a leading provider of access management solutions for healthcare and other mission-critical industries, today introduced Agentic Identity Management, new platform capabilities designed to secure and govern AI agents across healthcare environments.

As health systems increasingly adopt agentic AI to support clinicians and automate administrative and operational workflows, organizations face a growing challenge: ensuring AI agents can securely access clinical systems while maintaining the strict governance, compliance, and safety requirements unique to healthcare.

Imprivata is uniquely positioned to solve this challenge through decades of experience securing healthcare identities and workflows across thousands of hospitals and healthcare delivery organizations globally. Imprivata is now extending its trusted healthcare access management platform to securely integrate AI agents across both modern and legacy healthcare systems, enabling organizations to safely unlock the productivity benefits of AI without disrupting existing infrastructure.

“Healthcare is entering the era of agentic AI, where software can take on tasks that help care providers manage growing workloads and allow organizations to deliver better patient care,” said Fran Rosch, CEO of Imprivata. “Imprivata enables these agents to operate productively across clinical and operational systems while ensuring that every action is secure, governed, and compliant with healthcare regulations.”

Enabling AI productivity while keeping clinicians in control

AI agents are increasingly being deployed to assist clinicians with tasks such as clinical documentation, patient triage, care coordination, and prescription workflows. These technologies have the potential to dramatically reduce administrative burden and improve patient outcomes by allowing clinicians to focus on care rather than manual processes. However, as AI systems begin to perform more complex and regulated healthcare tasks, organizations must ensure that clinicians remain appropriately in the loop and that agent activity is governed with the same identity and access controls applied to human users.

Imprivata Agentic Identity Management treats AI agents as managed identities within the organization’s identity and security framework. By authenticating agents, enforcing least-privilege access, and monitoring activity in real time, Imprivata enables healthcare organizations to safely deploy AI agents that enhance clinician productivity while maintaining oversight and accountability.

Because Imprivata already secures access across a wide range of healthcare environments, the platform can immediately broker secure access for AI agents across EHRs, clinical systems, and legacy infrastructure with which many other access management and identity security solutions cannot easily integrate. This allows health systems to adopt AI agents faster while ensuring access is tightly controlled.

Addressing healthcare’s unique AI security risks

Healthcare environments present uniquely complex governance challenges for AI adoption, including strict regulatory requirements, patient safety concerns, and the need for continuous system availability. Recent research has demonstrated how AI systems can be manipulated through prompt injection attacks, potentially leading to harmful outputs or unauthorized actions. Without proper governance, AI agents could inadvertently introduce serious risks, including:

• Patient safety risks from corrupted or manipulated clinical data
• Operational disruption caused by runaway automation across scheduling, pharmacy, or lab systems
• Financial fraud or exposure of protected health information (PHI)

Imprivata Agentic Identity Management extends the company’s established identity security model to AI-driven systems, enabling organizations to deploy agents safely while maintaining visibility and control over how those agents interact with critical infrastructure. With Agentic Identity Management, organizations can:

• Provision AI agents as managed identities with defined roles and access permissions
• Broker secure connections using short-lived tokens that protect credentials
• Maintain a registry of authorized agents and discover unmanaged agents
• Monitor and audit agent activity across systems
• Revoke or limit agent access in real time when necessary
• Enforce least-privilege access across both modern and legacy healthcare systems

By applying Zero Trust principles, privileged access controls, and continuous monitoring to AI agents, Imprivata helps healthcare organizations accelerate AI adoption while protecting patient safety, system integrity, and regulatory compliance.

“Our goal is to help healthcare organizations unlock the productivity benefits of AI without introducing new risk,” said Rosch. “By governing AI agents the same way we govern human identities—and by keeping clinicians in the loop—we enable organizations to confidently deploy AI across the healthcare enterprise.”

Interested in learning more?  
Imprivata offers several ways to learn more about Agentic Identity Management, including: 

• Visit Imprivata at booth #2453 at this week’s HIMSS Conference in Las Vegas to see the new solution in action
• Join our upcoming webinar “Introducing Agentic Identity Management: Securing AI Agent Access.” Register here.

About Imprivata 
Imprivata delivers simple and secure access management solutions for healthcare and other mission-critical industries to ensure every second of crucial work is both frictionless and secure. Imprivata’s platform of innovative, interoperable access management and privileged access security solutions enable organizations to fully manage and secure all enterprise and third-party identities to facilitate seamless user access, protect against internal and external security threats, and reduce total cost of ownership. For more information, visit www.imprivata.com.    
 
Media Contact 
press@imprivata.com  

VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland




VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland

— The new pricing structure is made available as of February for 32,13 SEK per day at pharmacies throughout Sweden

AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) — VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious medical conditions and life-limiting diseases, today announced the new pricing structure of QSIVA^® hard modified-release capsules phentermine/topiramate is available as of February in Sweden.

“At VIVUS, we are proud to offer more accessible and affordable solutions for patients with overweight or obesity,” said John Amos, Chief Executive Officer at VIVUS LLC. “QSIVA offers competitive pricing on a price-per-kilogram basis across the approved European countries, reinforcing our commitment to expanding access to effective treatment. In clinical studies, QSIVA has demonstrated clinically meaningful and sustained weight loss when combined with diet and exercise. Additional clinical research has shown that QSIVA, when used in combination with digital lifestyle intervention, was associated with greater weight loss and improvements in cardiovascular risk measures compared with lifestyle intervention alone. With this price reduction, we encourage physicians to inform patients of the convincing impact of QSIVA, and how this therapy can fit seamlessly into patient’s lifestyle.”

Globally, obesity and overweight pose significant public health challenges, impacting millions of people across Europe. These conditions increase the risk of various health problems, making them leading causes of death like heart disease, stroke, and diabetes. Patients urgently require effective treatments to enhance their quality of life. In conjunction with a healthy lifestyle, QSIVA can assist patients in achieving and maintaining healthy weight goals, thereby significantly reducing the associated health risks. QSIVA is currently available in Sweden, Denmark, Finland, Iceland, and Poland with more countries coming in the future.

About VIVUS
VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit https://www.vivus.com.

About QSIVA
QSIVA (the European brand name for QSYMIA) is approved in Sweden, Denmark, Finland, Iceland, and Poland. QSIVA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of QSIVA on reducing cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSIVA in combination with other products intended for weight loss, including prescription and over-the-counter drugs and herbal preparations, have not been established. For more information on QSIVA, please visit QSIVA.eu. The website is accessible for healthcare professionals only through registration.

Important Safety Information for QSIVA
QSIVA^® hard modified-release capsules phentermine/topiramate is contraindicated in pregnancy and in women of childbearing potential not using highly effective contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); in patients with hypersensitivity to sympathomimetic amines, to the active substances, or to any of the excipients in QSIVA.

QSIVA can cause foetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use highly effective contraception while taking QSIVA. If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should consult promptly with their doctor. The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, depression, constipation, and dry mouth.

Forward-Looking Statements
Important Information and Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and/or covered by the “Bespeaks Caution” doctrine applied by the courts under the antifraud provisions of the federal securities laws, and other applicable provisions of the federal securities laws. Such forward-looking statements are based on current expectations, management’s beliefs, and certain assumptions made by the Company’s management. These statements may be identified by the use of forward-looking words such as “will,” “shall,” “may,” “believe,” “expect,” “forecast,” “intend,” “anticipate,” “predict,” “should,” “plan,” “likely,” “opportunity,” “estimated,” and “potential,” and/or the negative use of these words or other similar words. All forward-looking statements included in this document are based on the Company’s current expectations, and the Company assumes no obligation to update any such forward-looking statements except to the extent otherwise required by law.

Forward-looking information about QSIVA, including statements regarding its clinical efficacy, safety profile, the anticipated impact of the price reduction on patient access and commercial performance, and its role in long-term obesity management, involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied in this press release.

Risks related to QSIVA include the potential benefits of the price reduction on patient access and uptake, the impact of revised pricing strategies on revenue and commercial performance, the continued success of pharmacy partnerships across the Nordics and Poland, competitive developments in the weight management market including injectable medications, and whether QSIVA will continue to be commercially successful in approved markets.

General risks include the ability to successfully manage commercial programs across multiple international markets; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of QSIVA; supply chain challenges; and competitive developments in the obesity and weight management therapeutic area.

The above factors, risks, and uncertainties are difficult to predict, contain uncertainties that may materially affect actual results, and may be beyond the Company’s control. New factors, risks, and uncertainties emerge from time to time, and it is not possible for management to predict all such factors, risks, and uncertainties. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore any of these statements may prove to be inaccurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by the Company or any other person that the Company’s objectives and plans will be achieved. These forward-looking statements speak only as of the date such statements were made or any earlier date indicated, and the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in underlying assumptions, or otherwise, unless otherwise required by law. This announcement is made in accordance with applicable securities regulations including the EU Market Abuse Regulation.

Contacts

VIVUS BV
T: +31 20 262 0959

Media – FINN Partners
Julian Tyndale-Biscoe
julian.tyndale-biscoe@finnpartners.com
T: +44 20 7046 8280